More Images
COVID vaccines will have a new formulation this year, according to a decision announced today by the US Food and Drug Administration that will focus efforts on circulating variants. The move pushes last year's bivalent vaccines out of circulation because they will no longer be authorized for use in the United States.

The updated mRNA vaccines for 2023-2024 are being revised to include a single component that corresponds to the Omicron variant XBB.1.5. Like the bivalents offered before, the new monovalents are being manufactured by Moderna and Pfizer.

The new vaccines are authorized for use in individuals age 6 months and older. And the new options are being developed using a similar process as previous formulations, according to the FDA. Head over to Medscape to read the full story.